Syros Announces Closing of Concurrent Public Offerings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Syros Pharmaceuticals (SYRS) PT Lowered to $24 at Piper Jaffray
April 10, 2019 9:19 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Syros Pharmaceuticals (NASDAQ: SYRS) to $24.00 (from $28.00) while maintaining a Overweight rating. Syros recently raised gross proceeds of $70 million, bringing estimated pro forma cash to ~$165 million.
Syros is developing potentially best-in-class CDK7 inhibitors.... More
